160 related articles for article (PubMed ID: 34844889)
1. The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC.
Twelves C; Bartsch R; Ben-Baruch NE; Borstnar S; Dirix L; Tesarova P; Timcheva C; Zhukova L; Pivot X
Clin Breast Cancer; 2022 Apr; 22(3):223-234. PubMed ID: 34844889
[TBL] [Abstract][Full Text] [Related]
2. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
[TBL] [Abstract][Full Text] [Related]
3. Current Treatment Patterns Among Postmenopausal Women with HR+/HER2- Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study.
Goldschmidt D; Dalal AA; Romdhani H; Kelkar S; Guerin A; Gauthier G; Wu EQ; Niravath P; Small T
Adv Ther; 2018 Apr; 35(4):482-493. PubMed ID: 29582246
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
Quek RGW; Mardekian J
Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
[TBL] [Abstract][Full Text] [Related]
5. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
Jacquet E; Lardy-Cléaud A; Pistilli B; Franck S; Cottu P; Delaloge S; Debled M; Vanlemmens L; Leheurteur M; Guizard AV; Laborde L; Uwer L; Jacot W; Berchery D; Desmoulins I; Ferrero JM; Perrocheau G; Courtinard C; Brain E; Chabaud S; Robain M; Bachelot T
Eur J Cancer; 2018 May; 95():93-101. PubMed ID: 29655061
[TBL] [Abstract][Full Text] [Related]
6. Tumor hormone/HER2 receptor status and pharmacologic treatment of metastatic breast cancer in Western Europe.
Gao S; Barber B; Schabert V; Ferrufino C
Curr Med Res Opin; 2012 Jul; 28(7):1111-8. PubMed ID: 22587480
[TBL] [Abstract][Full Text] [Related]
7. Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre.
Twelves C; Cheeseman S; Sopwith W; Thompson M; Riaz M; Ahat-Donker N; Myland M; Lee A; Przybysz R; Turner S; Hall G; Perren T
BMC Cancer; 2020 Jan; 20(1):53. PubMed ID: 31964373
[TBL] [Abstract][Full Text] [Related]
8. Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities.
Conlin AK; Seidman AD
Clin Breast Cancer; 2008 Jun; 8(3):215-23. PubMed ID: 18650151
[TBL] [Abstract][Full Text] [Related]
9. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.
Hao Y; Li N; Fang AP; Koo V; Peeples M; Kageleiry A; Wu EQ; Guérin A
Adv Ther; 2016 Jun; 33(6):983-97. PubMed ID: 27216253
[TBL] [Abstract][Full Text] [Related]
10. Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA.
Lin PL; Hao Y; Xie J; Li N; Ohashi E; Koo V; Wu EQ
Expert Opin Pharmacother; 2015; 16(14):2101-11. PubMed ID: 26290278
[TBL] [Abstract][Full Text] [Related]
11. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer.
Wilson FR; Varu A; Mitra D; Cameron C; Iyer S
Breast Cancer Res Treat; 2017 Nov; 166(1):167-177. PubMed ID: 28752187
[TBL] [Abstract][Full Text] [Related]
12. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry.
Hartkopf AD; Huober J; Volz B; Nabieva N; Taran FA; Schwitulla J; Overkamp F; Kolberg HC; Hadji P; Tesch H; Häberle L; Ettl J; Lux MP; Lüftner D; Wallwiener M; Müller V; Beckmann MW; Belleville E; Wimberger P; Hielscher C; Geberth M; Fersis N; Abenhardt W; Kurbacher C; Wuerstlein R; Thomssen C; Untch M; Fasching PA; Janni W; Fehm TN; Wallwiener D; Brucker SY; Schneeweiss A
Breast; 2018 Feb; 37():42-51. PubMed ID: 29100043
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010).
Macalalad AR; Hao Y; Lin PL; Signorovitch JE; Wu EQ; Ohashi E; Zhou Z; Kelley C
Curr Med Res Opin; 2015 Feb; 31(2):263-73. PubMed ID: 25350226
[TBL] [Abstract][Full Text] [Related]
14. Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer.
Paplomata E; Zelnak A; Santa-Maria CA; Liu Y; Gogineni K; Li X; Moreno CS; Chen Z; Kaklamani V; O'Regan RM
Clin Breast Cancer; 2019 Jun; 19(3):188-196. PubMed ID: 30745109
[TBL] [Abstract][Full Text] [Related]
15. The impact of new systemic therapies on survival and time on hormonal treatment in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: A population-based study in British Columbia from 2003 to 2013.
Le D; Speers C; Thompson L; Gondara L; Nichol A; Lohrisch C
Cancer; 2020 Mar; 126(5):971-977. PubMed ID: 31750938
[TBL] [Abstract][Full Text] [Related]
16. Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer.
Huppert LA; Gumusay O; Idossa D; Rugo HS
CA Cancer J Clin; 2023; 73(5):480-515. PubMed ID: 36939293
[TBL] [Abstract][Full Text] [Related]
17. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
Vernieri C; Corti F; Nichetti F; Ligorio F; Manglaviti S; Zattarin E; Rea CG; Capri G; Bianchi GV; de Braud F
Breast Cancer Res; 2020 Apr; 22(1):33. PubMed ID: 32252811
[TBL] [Abstract][Full Text] [Related]
18. Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review.
Nagaraj G; Ma CX
Adv Ther; 2021 Jan; 38(1):109-136. PubMed ID: 33190190
[TBL] [Abstract][Full Text] [Related]
19. Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
Abraham J; Coleman R; Elias A; Holmes FA; Kalinsky K; Kittaneh M; Lower E; Mahtani R; Terry Mamounas E; Pegram M; Vogel C;
Breast Cancer Res Treat; 2018 Aug; 171(1):11-20. PubMed ID: 29725889
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US.
Xie J; Hao Y; Li N; Lin PL; Ohashi E; Koo V; Signorovitch JE; Wu EQ; Yardley DA
Curr Med Res Opin; 2015 Jun; 31(6):1095-103. PubMed ID: 25971725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]